Stem cell therapy for neurologic, cardiovascular and autoimmune conditions

You want a straight read on whether cell therapy can help.

Celva's physician team at Hospital Angeles, Tijuana reads your records first, and if cell therapy isn't the right tool for you, they tell you.

Book a call See who this can help
Two Celva clinicians reviewing brain MRI slices on a monitor during a case review

What cell therapy can do here, and what it can't

There is credible evidence that mesenchymal stem cells (cells that signal the immune system and the tissue around them) can calm neuroinflammation and, in specific conditions, support function.

There is not yet credible evidence that they reverse established neurodegeneration, regrow myelin at scale, or restore lost neurons in a clinically meaningful way.

The work sits between those two statements. For some patients, with the right condition, at the right stage, and with realistic expectations, that's worth trying. For many, it isn't.

It is not a cure, and whether to treat again is decided at review. With a progressive condition, the aim is to hold ground and extend it.

Could this help you?

Cell therapy works on biology, not on a diagnosis: the inflammation, immune signaling and tissue your body still has to work with. Whether your situation has something to influence is usually only clear once the physicians look.

  • Active biology

    Is there inflammation or immune activity to influence? That is where the cells do most of their work, and it shows up across very different diagnoses.

  • Tissue to work with

    Is there still structure to support? Earlier in a condition usually leaves more to build on than later, which is a reason to ask sooner.

  • Stable footing

    Are you steady on your current care, with your own specialists directing it? This adds to that care. It doesn't replace your medication or your doctors.

  • Realistic goals

    The aim is a change you can notice. Knowing what better would mean for you is part of deciding whether this is worth doing.

It comes up most with Parkinson's, recovery after a stroke, MS, dysautonomia and ischemic heart disease, along with other neurologic, cardiovascular, autoimmune and post-viral conditions. These are examples, not a checklist.

Read who is a fit

How the cells work in the body

Given by IV, the cells travel through the bloodstream and signal. They are designed to calm chronic inflammation and immune activity that has turned against the body, without suppressing the immune system the way steroids and biologics do.

Read moreShow less

Many neurologic, autoimmune, post-viral and cardiovascular conditions have that immune imbalance near their center, so it is the part of the mechanism that leads. For neurologic cases, treatment starts from umbilical-cord (Wharton's jelly) cells, chosen because they release more of the growth factors nerve cells depend on (BDNF, NGF and GDNF) than marrow-derived cells. It is signaling, not tissue replacement, which is also why it has limits.

Every case is read by the physician team

  1. A call with your coordinator

    About 15 minutes with a Celva patient coordinator, and not a sales call.

  2. Your records

    Full history, imaging, specialist notes and every treatment you've tried, including what didn't work.

  3. Review by the physician team

    The physician team, with outside consultation in neurology, rheumatology, cardiology or another field as needed. They look at disease stage and medication stability. When the case merits it, an extended call with the physician team follows.

  4. A decision, in writing

    One of three answers.

    • Accept, with a specific plan, what to expect and how it will be measured.

    • Decline, with the reason and any referral we can make.

    • Defer, with what would reopen the case.

See how a case is evaluated
Dr. Alejandro Castillo
“I wanted so badly to accept him. He’d already flown to four clinics. What he needed, what would have been honest, was hospice planning and time with his family. We said so. He thanked us. That’s the one I think about.”
Dr. Alejandro Castillo, MD
Interventional radiologist, physician team

The most common reason the team says no is that the disease is too far along for this to make a difference. When that's the answer, or something needs a hospital now, you hear it plainly, with where to go instead.

Read what to expect

If you're accepted, what treatment looks like

Most plans use umbilical-cord MSCs by IV as the foundation, often blended with bone-marrow MSCs depending on your condition, its stage and your history. The dose is set by your weight and tuned to severity. Whether another session follows is decided at review. See why we use more than one cell type

First treatment

Before it, we record a baseline of 12 or more functional measures. A nurse runs your first infusion under the attending physician's supervision, on site the same day, with labs only when the physician team asks for them. Follow-up calls come at 1 week, then at 1, 3 and 6 months, then once a year.

First review, at about three months

Together you look at how you feel, your symptoms and anything your own labs show. It is the whole picture, not one number, and you decide together to continue, pause or stop. A further dose is never automatic.

If you're responding

Treatment continues, with dose and timing adjusted to how you respond, and a review at every check-in.

Wrapping up

When the benefit has consolidated, or more treatment isn't adding enough, the program closes on the terms you agreed at the start. You leave with your full records and a clear picture of what changed and what to watch.

Questions families ask

Why are you so selective about who you accept?
Because the biology here is harder (neuroinflammation, autoimmunity, post-viral states, vascular disease), and the harm of selling false hope is measured in a family's time, energy, and trust. Even among carefully chosen patients, not everyone responds.
Do you coordinate with my specialist?
We're glad to involve them. In practice, many U.S. specialists can't formally recommend or coordinate on a therapy outside standard care, so we don't require your specialist's sign-off to move forward. What we do is give you your full records to share with whomever you choose. If your specialist is open to it, we'll share directly; if not, you leave with everything they would need to pick your care back up.
What happens if nothing measurable changes in my first 90 days?
A flat reading at three months is common, and on its own it isn't a reason to stop: these conditions can take longer than that to read. We review how you feel and function alongside any labs of your own. Whether to treat again is decided at review, and you continue only while there is a reason to. If it isn't helping, they say so and stop, and you get a written summary of what was measured, expected and observed.
Is this a clinical trial?
No. This is a physician-led treatment program licensed in Mexico and regulated by COFEPRIS. We follow every patient closely in clinical follow-up, but we are not an IRB-registered trial site. If a trial exists for your condition at a major center and you might qualify, we'll tell you. Sometimes that is the better recommendation.
What's the downside I should know about?
Two. First: there is a real chance that the treatment does not produce measurable change, and the program may end without the result you hoped for. Second: unlike joint patients, systemic and complex patients often face the slow, ambiguous grief of "did it work?" We structure measurement to cut through that. Not every patient wants that level of cold clarity, and it matters to know that going in.

Start with the evaluation

A call with a patient coordinator, your records, and a review by the physician team. If you're accepted, you get what to expect in writing. If not, you hear why, and where to look next.

Book a call